USPTO serial 87890475
SINOVANT
Reviewed by CopyMark Law Group
Reg. 6016121Status 710
- Filing date
- Status date
- Registration date
- Mar 24, 2020
- Examiner
- GOLD, BARBARA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with SINOVANT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Brian J. Winterfeldt
BRIAN J. WINTERFELDT WINTERFELDT IP GROUP1601 K Street, NWSuite 1050Washington, DC 20006Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals and medical preparations for the treatment of abdominal pain, acute kidney injury, anemia, autoimmune disorders, dementia, bacterial infections, cancers, cardiovascular disease, central nervous system disorders, delayed graft function, dermatitis, dermatologic diseases, diabetes, diseases associated with enzyme deficiency, gastrointestinal diseases, genetic disorders, gynecological diseases, hematologic diseases, hepatitis, viral hepatitis, hypertension, immune disorders, immunodeficiency, infectious diseases, infertility, lung diseases, metabolic disorders, myopathy, obstetric disorders, oncologic diseases, psychiatric disorders, renal diseases, respiratory diseases, skin conditions, urinary symptoms, urological diseases, uterine fibroids, endometriosis, prostate cancer, female infertility, Farber Disease, Complete DiGeorge Anomaly, Parkinson's Disease, Tay-Sachs Disease, Sandhoff Disease, GM-1 Gangliosidosis, oculopharyngeal muscular dystrophy, overactive bladder, irritable bowel syndrome, psoriasis, atopic dermatitis, vitiligo, primary focal hyperhidrosis, acne vulgaris, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, sickle cell disease, ß-thalassemia, community-acquired bacterial pneumonia, intrahepatic cholangiocarcinoma, hepatitis B, bacteremia, autism, amyotrophic lateral sclerosis and frontotemporal dementia; biological preparations for medical purposes, namely, the treatment of abdominal pain, acute kidney injury, anemia, autoimmune disorders, dementia, bacterial infections, cancers, cardiovascular disease, central nervous system disorders, delayed graft function, dermatitis, dermatologic diseases, diabetes, diseases associated with enzyme deficiency, gastrointestinal diseases, genetic disorders, gynecological diseases, hematologic diseases, hepatitis, viral hepatitis, hypertension, immune disorders, immunodeficiency, infectious diseases, infertility, lung diseases, metabolic disorders, myopathy, obstetric disorders, oncologic diseases, psychiatric disorders, renal diseases, respiratory diseases, skin conditions, urinary symptoms, urological diseases, uterine fibroids, endometriosis, prostate cancer, female infertility, Farber Disease, Complete DiGeorge Anomaly, Parkinson's Disease, Tay-Sachs Disease, Sandhoff Disease, GM-1 Gangliosidosis, oculopharyngeal muscular dystrophy, overactive bladder, irritable bowel syndrome, psoriasis, atopic dermatitis, vitiligo, primary focal hyperhidrosis, acne vulgaris, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, sickle cell disease, ß-thalassemia, community-acquired bacterial pneumonia, intrahepatic cholangiocarcinoma, hepatitis B, bacteremia, autism, amyotrophic lateral sclerosis and frontotemporal dementia; drugs and pharmaceutical preparations, namely, pills, tablets, capsules, caplets, liquid drops, sachets, elixirs, topical preparations, ointments, syrups, tinctures, solutions and wound dressings, namely, silicone gel sheets for wound and scar covering and healing, for the treatment of abdominal pain, acute kidney injury, anemia, autoimmune disorders, dementia, bacterial infections, cancers, cardiovascular disease, central nervous system disorders, delayed graft function, dermatitis, dermatologic diseases, diabetes, diseases associated with enzyme deficiency, gastrointestinal diseases, genetic disorders, gynecological diseases, hematologic diseases, hepatitis, viral hepatitis, hypertension, immune disorders, immunodeficiency, infectious diseases, infertility, lung diseases, metabolic disorders, myopathy, obstetric disorders, oncologic diseases, psychiatric disorders, renal diseases, respiratory diseases, skin conditions, urinary symptoms, urological diseases, uterine fibroids, endometriosis, prostate cancer, female infertility, Farber Disease, Complete DiGeorge Anomaly, Parkinson's Disease, Tay-Sachs Disease, Sandhoff Disease, GM-1 Gangliosidosis, oculopharyngeal muscular dystrophy, overactive bladder, irritable bowel syndrome, psoriasis, atopic dermatitis, vitiligo, primary focal hyperhidrosis, acne vulgaris, pulmonary arterial hypertension, idiopathic pulmonary fibrosis, sickle cell disease, ß-thalassemia, community-acquired bacterial pneumonia, intrahepatic cholangiocarcinoma, hepatitis B, bacteremia, autism, amyotrophic lateral sclerosis and frontotemporal dementia; veterinary preparations, namely, chemical reagents, plant extracts, veterinary vaccines, and anti-infective products for veterinary use; stem cells for medical purposes; stem cells for veterinary purposes; stem cells for medical or veterinary use; food supplements, namely, anti-oxidants; antioxidant enriched coffee for medical purposes; medical or veterinary preparations, namely, antioxidants; pharmaceutical preparations, namely, blood clotting aids and delivery systems for the treatment of intestinal bacteria, pain, bacterial infections, and wounds; sanitary preparations for medical purposes; dietetic foods adapted for medical or veterinary purposes; food for babies; dietary supplements for humans and animals; medical plasters; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides | SECTION 8 - CANCELLED | — |
| 010 | Medical apparatus and instruments, namely, patches, and sub-cutaneous drug delivery devices sold empty for drug delivery, pain management, physical rehabilitation, surgery, invasive and non-invasive ventilation, kidney dialysis treatment, treating vascular bifurcations and respiratory diseases, monitoring vital signs, oximetry, gas analysis, blood properties and respiratory events; surgical, dental and veterinary apparatus and instruments for general surgery, orthopedic surgery, ophthalmic surgery, measuring wounds, cutting human or animal tissue and organs, namely, scalpels, blades, staplers, clamps, perforated strips, panels and surgical table straps, stretcher straps, patient positioning straps, breast prostheses, hand prostheses, hip prostheses, joint prostheses, dental prostheses, staple-shaped prostheses for the spinal column, staple-shaped prostheses of vertebral discs, bone prostheses, fasteners, wrenches, screwdrivers, screw taps, drills, hammers, pliers and bone chisels for use in the medical and dental fields; artificial limbs, eyes and teeth; orthopedic articles, namely, surgical prostheses, knee prostheses, toe prostheses, hip prostheses, hip joint implants, dental implants; suture materials; therapeutic and assistive devices adapted for the disabled, namely, assistive listening device, transfer boards for hearing impaired or mobility-impaired persons; massage apparatus; apparatus, devices and articles for nursing infants, namely, nursing bottles, pacifier cloths for attachment to infant pacifiers, infant sleep positioner cushions; adult sexual stimulation aids, namely, artificial penises, penis enlargers, vibrators, benwa balls, and artificial vaginas | SECTION 8 - CANCELLED | — |
| 035 | Retail and wholesale store services featuring pharmaceutical and biological preparations; advertising services; business management; business administration for others; providing office functions | SECTION 8 - CANCELLED | — |
| 042 | Pharmaceutical and biological research and development services; scientific and technological services, namely, medical research and scientific research, chemical analysis in the healthcare and biomedical fields; research and development in the pharmaceutical and biotechnology fields; development of pharmaceutical preparations and medicines; conducting early evaluations in the field of new pharmaceuticals; testing, inspection, research, or development of pharmaceutical preparations for gene therapy; scientific and technological services in the nature of scientific data processing analysis services; rental of data processing apparatus, updating and rental of software for data processing, rental services relating to data processing equipment and computers, and rental of computer software, data processing equipment and computer peripheral devices; pharmaceutical and biomedical research services; scientific research in the field of pharmaceutical and biologic therapeutic preparations and medical devices; pharmaceutical research and development in the field of subcutaneous drug delivery devices sold empty and the medicines to be used in connection therewith; providing scientific research information in the field of pharmaceuticals and biomedicine and medical devices; scientific and technological services, namely, research and design in the field of healthcare and biomedicine products and services, pharmaceuticals, clinical trials, and post-market trials; industrial analysis and research services in the field of healthcare and biomedicine products and services, pharmaceuticals, clinical trials, post-market trials; design and development of computer hardware and software | SECTION 8 - CANCELLED | — |
| 044 | Medical services; veterinary services; hygienic and beauty care for human beings or animals; horticultural services; agriculture services, namely, insecticide spraying, vermin exterminating, pest control service; forestry services, namely, insecticide spraying, vermin exterminating, and pest control services | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Roivant China Holdings Ltd.
- Other trademarks owned by Roivant China Holdings Ltd.
- Other trademarks owned by Roivant China Holdings Ltd.
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 035
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named SINOVANT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 13, 2026 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Mar 24, 2025 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Mar 24, 2020 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 31, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 7, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 7, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 18, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 3, 2019 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Nov 28, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 22, 2019 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Nov 22, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 22, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 22, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 22, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 22, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 27, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 27, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 27, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 24, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 23, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 23, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 25, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 25, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 26, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 26, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 22, 2019 | ALIE | ASSIGNED TO LIE | — |
| Feb 15, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 15, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 15, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 15, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 15, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| May 3, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 27, 2018 | NWAP | NEW APPLICATION ENTERED | — |